These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36194133)

  • 41. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
    Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
    J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
    Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    ACS Cent Sci; 2023 Aug; 9(8):1658-1669. PubMed ID: 37637734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
    Zhu M; Fu T; You M; Cao J; Yang H; Chen X; Zhang Q; Xu Y; Jiang X; Zhang L; Su H; Zhang Y; Shen J
    Bioorg Med Chem; 2023 May; 87():117316. PubMed ID: 37187077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.
    Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM
    J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
    Huang C; Zeng R; Qiao J; Quan B; Luo R; Huang Q; Guo N; Li Y; Long X; Ma R; Xia A; Fang Z; Wang Y; Li Y; Zheng Y; Li L; Lei J; Yang S
    Eur J Med Chem; 2023 Nov; 259():115657. PubMed ID: 37517202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of Novel Chinese Medicine Compounds Targeting 3CL Protease by Virtual Screening and Molecular Dynamics Simulation.
    Cheng J; Hao Y; Shi Q; Hou G; Wang Y; Wang Y; Xiao W; Othman J; Qi J; Wang Y; Chen Y; Yu G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
    Bello M; Hasan MK
    J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
    Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
    De Marco Verissimo C; López Corrales J; Dorey AL; Cwiklinski K; Lalor R; Calvani NED; Jewhurst HL; Flaus A; Doyle S; Dalton JP
    Epidemiol Infect; 2022 Jun; 150():e128. PubMed ID: 35723031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
    Pang X; Xu W; Liu Y; Li H; Chen L
    Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
    Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.